Advertisements

Octostim

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Octostim

Quick Facts

Property Description
Active ingredient Desmopressin acetate
Form Aqueous solution for injection, Nasal spray
Pharmacological class Antidiuretic Hormone Analog
General Purpose Fluid balance regulation, Coagulation support
Origin Synthetic peptide

What is Octostim? A Vasopressin Analog Definition

Octostim is a specialized, prescription-only medication primarily classified as an antidiuretic hormone analog. Its active component is desmopressin acetate (Desmopressin), a potent synthetic peptide that mimics the action of the body's natural hormone, vasopressin. This pharmacological differentiation results in desmopressin having a much higher selectivity for V2 receptors, which primarily control the retention of water in the kidneys. This targeted action is a crucial distinguishing feature when compared to the native hormone.

Composition and Form: The Single-Ingredient Aqueous Solution

Octostim is a single-ingredient product composed solely of desmopressin acetate, typically presented as a sterile, aqueous solution for injection or as a nasal spray solution. This liquid formulation and the corresponding administration routes (intravenous, subcutaneous, or intranasal) are essential because the drug is a peptide; oral ingestion would cause it to be rapidly degraded by digestive enzymes, preventing effective systemic absorption. The manufacturing focus on the injectable and nasal forms caters specifically to patient groups requiring highly controlled systemic access.

General Purpose: Regulation of Fluid Balance and Hemostasis Support

The general purpose of Octostim is dual-action, centered on regulating the body's fluid balance and supporting temporary coagulation. In its primary antidiuretic function, the medication helps manage fluid output by signaling the kidneys to increase the re-absorption of water into the bloodstream, which results in a reduction of excessive urine volume. Concurrently, the drug transiently enhances hemostasis by stimulating the release of stored clotting proteins, including coagulation factor VIII and von Willebrand factor, from the vascular lining. This temporary support makes it relevant in scenarios requiring increased clotting ability.

Advertisements

What side effects are possible with Octostim?

Possible Side Effects and Safety Information

Octostim's safety profile is predominantly characterized by its potential to affect fluid and electrolyte balance due to its potent antidiuretic effect. The most serious adverse reaction documented in regulatory labeling is severe hyponatraemia (low blood sodium concentration), which can rarely lead to serious neurological outcomes, including seizures or coma.

Adverse reactions are officially categorized by frequency and the body's system-organ classes (SOC). Common side effects, observed in official reports, typically affect the nervous system and gastrointestinal tract, including headache, nausea, abdominal pain, and general fatigue.

Safety constraints necessitate caution or contraindication in specific populations. Regulatory documents highlight an increased risk of hyponatraemia in older adults and mandate avoidance in patients with moderate to severe renal impairment or known cardiac insufficiency.

Certain effects are noted to be dose-related, such as facial flushing and a transient fall in blood pressure, which are often observed at higher therapeutic doses. Overall, the official safety documentation establishes that appropriate patient selection and adherence to the necessary fluid management are critical elements of the risk profile, focusing on avoiding serious electrolyte imbalance.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical manifestations and regulator-mandated emergency actions associated with an overdose of Octostim (desmopressin acetate).


Documented Overdose Manifestations

The most significant and formally documented consequence of desmopressin overdose is hyponatremia (low sodium in the blood), which results from the drug's potent antidiuretic effect leading to excessive water retention. Symptoms listed in regulatory information include headache, nausea, vomiting, rapid weight gain, confusion, and drowsiness/lethargy.

Category Official Manifestation
Primary Finding Hyponatremia (decreased serum sodium concentration)
Severe Outcomes Seizures, coma, and cerebral edema

Required Emergency Actions

In the event of suspected overdose, immediate medical attention is required. The most serious outcomes are severe neurological events: Immediate medical help must be sought for symptoms such as confusion, seizures, or inability to be awakened.

Overdose treatment is officially described as symptomatic and supportive management. This management involves fluid restriction and correcting the underlying serum sodium imbalance. No specific antidote is known for desmopressin overdose. Regulatory documents note that pediatric and geriatric patients may be at greater risk for severe hyponatremia and require careful fluid management.

Advertisements

Therapeutic Uses of Octostim

What Octostim Treats: Main Uses and Benefits

Octostim is relevant for easing symptoms across two distinct clinical domains: assistance for coagulation and fluid balance management. Its use is generally appropriate in conditions marked by temporary physiological imbalance.

The medication is commonly used to help with abnormal bleeding tendencies relevant in conditions characterized by periods of heightened symptoms, including mild or moderate deficiencies in certain clotting factors, specifically Hemophilia A and Type I von Willebrand's disease, as well as bleeding related to certain forms of platelet dysfunction. It may provide supportive temporary assistance to the body’s clotting system, contributing to the goal of managing excessive bleeding during acute episodes or when patients undergo minor surgical procedures. This use contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Octostim is also applied across domains where additional symptomatic support is needed, primarily used in managing fluid loss symptoms common in central cranial diabetes insipidus. This condition is marked by the disruptive symptom cluster of polyuria (excessively high urine output) and intense polydipsia (thirst). The therapeutic benefit helps address symptom clusters that may become intense or disruptive, which contributes to improved comfort, particularly by reducing disruptive night-time urination. The medication is further considered relevant in a diagnostic context, commonly used to help with functional stability assessments.


Quick Fact: Relief for Disruptive Fluid Loss

Area of Use Symptom Category Primary Benefit
Coagulation Support Abnormal Bleeding Tendencies Assists in managing excessive bleeding during risk scenarios.
Fluid Balance Polyuria and Polydipsia Supports reduction of abnormally high urine volume.
Diagnostics Renal Function Evaluation Helps provide key diagnostic information for fluid balance disorders.
Advertisements

Eligibility and Restrictions for Use

Population Eligibility for Octostim (Desmopressin)

Official regulatory documents define strict criteria for who is eligible to use Octostim. Use is contraindicated (prohibited) for patients with a known history of hyponatraemia (low sodium levels), cardiac insufficiency (heart failure), unstable angina pectoris, or conditions requiring diuretic agents. It must also not be used if a patient has severe renal impairment (creatinine clearance below 50 mL/min), or certain von Willebrand's disease types (Type IIB, platelet-type).


Eligibility Restrictions

Population Group Regulatory Status
Pediatric Patients Not Established for coagulation uses in children younger than 3 months of age.
Older Adults Use requires caution due to increased risk of hyponatraemia; renal function must be monitored.
Pregnancy Should only be given if clearly needed and the benefit outweighs potential risk.
Lactation Use is not recommended while breastfeeding.

Treatment must be interrupted during acute illnesses like systemic infections or fever, or if the patient is overhydrated, until fluid balance is restored.

Advertisements

What should I know about interactions with other medicines?

Octostim's official interaction profile is characterized by pharmacodynamic interactions that increase the risk of fluid retention and low serum sodium (hyponatremia). The majority of documented interactions involve medications that enhance the antidiuretic effect of desmopressin.

Interaction Classifications

Interaction Classification Official Regulatory Constraint
Contraindicated Combinations Co-administration with loop diuretics and systemic or inhaled glucocorticoids is formally prohibited due to a high risk of severe hyponatremia.
Additive Antidiuretic Effects Requires caution and close monitoring when used with agents known to increase antidiuresis, including SSRIs, tricyclic antidepressants, NSAIDs, carbamazepine, and chlorpromazine.

Documented Interaction Constraints

  • Fluid Restriction: A mandatory interaction constraint for specific uses involves limiting fluid intake from one hour before administration until at least eight hours after to mitigate the interaction risk of water intoxication and hyponatremia.
  • Population Notes: The risk of interaction-related hyponatremia is explicitly noted to be greater in infants and elderly patients. Treatment may require interruption during acute intercurrent illnesses (e.g., systemic infections or gastroenteritis) due to risk of fluid imbalance.
  • Metabolic Interaction: Official regulatory data indicate that desmopressin is unlikely to undergo significant metabolism via the CYP450 enzyme system, suggesting a low risk of exposure modification through this pathway.
Advertisements

Mechanism of Action

Selective V2 Agonism for Fluid Regulation

Octostim's mechanism begins with its active component, desmopressin acetate, acting as a highly selective agonist on the Vasopressin 2 ( V2) receptors in the renal collecting ducts. This molecular binding initiates an intracellular signaling cascade, increasing cyclic AMP ( cAMP), which triggers the insertion of Aquaporin-2 ( AQP-2) water channels into the cell membrane . The resulting physiological effect is a substantial increase in water reabsorption back into the bloodstream, leading to modulation of systemic fluid balance.

Endothelial Factor Mobilization

The same V2 receptor is targeted on vascular endothelial cells, where its activation triggers rapid exocytosis of stored proteins from Weibel-Palade bodies. This mechanism mobilizes large quantities of von Willebrand factor ( vWF) and Coagulation Factor VIII ( FVIII) into the plasma. The physiological consequence is a transient increase in the activity of the intrinsic coagulation pathway.

Constraint: Factor Storage Depletion

The hemostatic mechanism is limited by its reliance on releasing pre-synthesized stores. Repeated, close-interval use can deplete these stores, resulting in tachyphylaxis (a diminished response to subsequent administration) until the cellular inventory is naturally replenished.

Advertisements

Dosage and Administration Information

How Octostim is Used: Administration Guidelines

Octostim is a specialized prescription medication used via specific routes and dosing schedules as directed by prescribing guidelines. It is available as a solution for injection (15 micrograms/mL) and a metered-dose nasal spray (1.5 mg/mL).


Administration Routes and Dosing

Administration Type Standard Adult Dose/Regimen Timing & Frequency Constraint
Injection (IV or SC) 0.3 micrograms/kg body weight Administer 30 minutes prior to a procedure; may be repeated 1 to 2 times at 12 to 24 hour intervals.
Nasal Spray (IN) 300 micrograms total dose (typically one spray per nostril) May be repeated at 12 hour intervals for a maximum of 2 to 3 days.

Preparation and Procedural Instructions

Proper use of Octostim is structured by required preparation steps and strict fluid management rules:

  • IV Preparation: The injection solution must be diluted in 50 to 100 mL of physiological saline. The resulting IV infusion must be administered slowly over a period of 15 to 30 minutes.
  • Nasal Use: The nasal spray pump must be primed before initial use to ensure the correct dose is delivered.
  • Fluid Restriction: Patients must limit fluid intake and drink only enough to satisfy thirst during treatment. This restriction is a mandatory condition of use.
  • Pediatric Use: The IV dose of 0.3 micrograms/kg is applied to children geq 3 months for the approved coagulation support uses.

These administration instructions ensure the medication is delivered accurately and define the standardized conditions, including necessary fluid restriction, that accompany the therapy.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Octostim


Evidence for Coagulation Support in Bleeding Disorders

Research was evaluated in clinical scenarios involving temporary bleeding issues in individuals with mild or moderate Factor VIII deficiency (Hemophilia A) or Type I von Willebrand's disease. The research base includes controlled randomized trials (RCTs) and systematic reviews.

Studies monitored biomarker levels like Factor VIII and VWF, and research describes patterns where these were outcomes related to systemic imbalance measured during short-term periods. Research also examined clinical outcomes, such as patterns related to the need for blood transfusions in surgical settings. However, studies indicate inter-individual variability in the measured response. Furthermore, evidence is limited in assessing whether the medicine was evaluated in individuals with severe forms of these conditions.


Evidence for Fluid Balance Management in Central Diabetes Insipidus

Octostim was studied for conditions associated with acute episodes, such as central cranial diabetes insipidus (CDI), marked by excessive urine output and thirst. Evidence includes pharmacokinetic/pharmacodynamic (PK/PD) studies that monitored the duration of antidiuretic action and measured changes in the rate of water reabsorption.

Research examined outcomes related to systemic imbalance, such as measured changes in urine osmolality and the rate of urine output. Studies report how symptoms evolved, focusing on outcomes reflecting daily activity, like the reduction in disruptive night-time urination (nocturnal voiding). The medicine is also evaluated in a diagnostic context to assess renal concentrating capacity. The foundational evidence for this use is often comprised of older studies, and modern, large-scale randomized trials focusing exclusively on CDI are still emerging.


Long-Term Studies and Durability of Response

Available research covers short-term physiological responses and, through systematic reviews, decades of clinical experience. For both coagulation support and fluid balance, many key physiological measurements were observed in studies over short-term follow-up durations. Long-term effects are not fully established regarding the consistency of Factor VIII, VWF, or sustained fluid balance over many years.


Identified Evidence Gaps and Areas of Uncertainty

Structural limitations are noted across the research base. Evidence quality varies across studies, and sample sizes were modest in many initial trials. Follow-up durations were limited, meaning there is limited information for long-term outcomes. Inter-individual variability in response remains a consistent finding, and the research does not determine whether an individual will respond similarly.

Key Studies & References

  1. MASAC Recommendations Regarding the Treatment of von Willebrand Disease (MASAC Document #266)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Octostim (FAQ)


Q: Is Octostim a hormone replacement therapy?

Octostim is officially classified as an antidiuretic hormone analog. This means the active ingredient, desmopressin, is a synthetic peptide that closely mimics the action of the body’s natural hormone, vasopressin.

However, it is generally not described using the specific term 'hormone replacement therapy.'


Q: How quickly does Octostim start working after administration?

Official prescribing information indicates that the hemostatic effect, which is the rise in necessary clotting factors, is typically reported to be observed within 30 minutes after the start of an intravenous infusion.


Q: How long do the effects of Octostim last?

According to official regulatory documents, the therapeutic effects—such as the elevation of clotting factors or antidiuretic action—generally last for approximately six to eight hours after administration.


Q: Are there any common foods or drinks that should be avoided when using Octostim?

Official prescribing information requires fluid restriction during treatment to manage the risk of developing dangerously low sodium levels in the blood.

Furthermore, regulatory information indicates that consuming alcohol may increase the risk of this low sodium condition, known as hyponatremia.


Q: Does Octostim cause long-term side effects?

Official safety data focuses primarily on acute risks, such as hyponatremia (low blood sodium).

The prescribing information notes that with repeated, close-interval use over time, the body may experience a diminished response, which is sometimes referred to as tachyphylaxis.


Q: Is Octostim safe to use if I have high blood pressure?

Regulatory documents advise that use requires caution in individuals with a history of heart disease and high blood pressure.

Some official labels for desmopressin products state they are contraindicated in cases of uncontrolled high blood pressure.


Q: Is it true that Octostim can be used before dental procedures?

Official indications state that the medicine is approved for use to help control bleeding in individuals with certain mild bleeding disorders who are undergoing minor surgical procedures.

This use aligns with the medicine's indication for patients undergoing minor surgical procedures.


Q: If I miss a planned dose, what is the general guidance?

The general guidance found in the prescribing information suggests administering a missed dose as soon as it is remembered.

If it is almost time for the next scheduled dose, the missed dose should generally be skipped, and treatment can continue on the regular schedule.


Q: Does alcohol interact with or change the effect of Octostim?

Yes. Official regulatory data indicates that consuming alcohol may increase the risk of developing hyponatremia, which is a dangerously low level of sodium in the blood. This risk is associated with the drug's antidiuretic effect.


Q: Is there a maximum number of times Octostim can be used in a month?

Regulatory documents define short-term limits for acute use, such as a maximum duration of two to three days for the nasal spray formulation.

Overall usage is generally limited by the risk of tachyphylaxis, a phenomenon where the effectiveness of the drug diminishes with too frequent administration.


Q: Can Octostim be used long-term for chronic conditions?

For the indication of Central Diabetes Insipidus (a fluid regulation disorder), long-term use is established.

However, for hemostatic support (bleeding disorders), use is generally acute or short-term and is limited by the potential for loss of effectiveness over time.


Q: Is Octostim available as a generic medicine?

Octostim is a brand-name medicine that contains the active ingredient desmopressin acetate.

The active ingredient desmopressin is available from multiple manufacturers as a generic drug in various formulations for specific indications.


Q: What is the purpose of Octostim in patients without hemophilia or von Willebrand disease?

The medicine is indicated for conditions associated with a deficiency of antidiuretic hormone, such as Central Diabetes Insipidus.

In this context, its purpose is to help regulate the body’s fluid balance by reducing excessive urine output.


Q: Does Octostim cause a change in heart rate?

Regulatory safety documents note that the medicine may cause a transient fall in blood pressure.

This change can sometimes lead to a compensatory increase in heart rate (tachycardia) as the body attempts to maintain circulation.


Q: Are there any specific laboratory tests that need to be monitored while using Octostim?

Regulatory guidance suggests monitoring specific laboratory parameters prior to and periodically during treatment.

These often include checking serum sodium concentration (to watch for hyponatremia) and monitoring other parameters like urine osmolality and Factor VIII activity depending on the condition being treated.


Q: Does using Octostim impact the ability to drive or operate machinery?

Official regulatory labels for the injection formulation state that the medicine has no or negligible influence on a person's ability to drive or safely use machinery.


Q: Why is Octostim sometimes given as a preventative measure?

Regulatory indications state that the medicine is used for the control and prevention of bleeding in patients with certain mild bleeding disorders.

This means it is often administered before planned events, such as surgical or dental procedures, rather than only after bleeding has begun.


Q: Is the effect of Octostim different depending on the type of administration (IV vs. intranasal)?

Official data confirms the intravenous route results in 100% bioavailability (the amount of drug that reaches the bloodstream).

The intranasal route has lower and more variable bioavailability, which can contribute to differences in the resulting concentration and duration of the medication's effect.


Q: What official documents describe the proper conditions for using Octostim?

The proper conditions and instructions for using the medicine are described in the official documents provided by government drug authorities.

These include the Summary of Product Characteristics (SmPC) in Europe and the Full Prescribing Information/Package Insert in the United States.


Q: Is Octostim ever used in emergency situations?

The drug's use is documented for managing acute episodes related to bleeding or antidiuretic hormone deficiency, often requiring administration in a controlled medical environment.


Q: What is the difference between Octostim and other desmopressin products?

Octostim is defined as the high-dose desmopressin product indicated primarily for hemostatic support (bleeding disorders).

Other desmopressin products are typically lower-dose formulations used mainly for fluid balance regulation (e.g., managing nocturnal enuresis or diabetes insipidus).

Advertisements

How should Octostim be stored and disposed of?

How to Store and Dispose of Octostim

Official regulatory guidelines require specific storage conditions that differ based on the product formulation.


Storage Requirements

Formulation Required Temperature Protection Constraints
Octostim Injection Store in a refrigerator (2 C to 8 C). Do not freeze. Keep in the original packaging to protect from light.
Octostim Nasal Spray Do not store above 25 C. Do not freeze. Keep the vial in the outer carton in an upright position.

Stability and Disposal Rules

  • Child Safety: All forms must be kept out of the sight and reach of children.
  • Post-Opening Stability: The nasal spray must be discarded after a specific period (e.g., six months) following the first opening.
  • Disposal: Unused or expired medication must not be disposed of via wastewater or household waste. Users are instructed to ask a pharmacist for guidance on proper pharmaceutical waste disposal, and used injection materials must be placed in a sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Octostim found in:

A-Z Index: